383 related articles for article (PubMed ID: 37569648)
1. Migraine Treatment: Towards New Pharmacological Targets.
Silvestro M; Iannone LF; Orologio I; Tessitore A; Tedeschi G; Geppetti P; Russo A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569648
[TBL] [Abstract][Full Text] [Related]
2. From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.
Tanaka M; Szabó Á; Körtési T; Szok D; Tajti J; Vécsei L
Cells; 2023 Nov; 12(22):. PubMed ID: 37998384
[TBL] [Abstract][Full Text] [Related]
3. Future targets for migraine treatment beyond CGRP.
Al-Hassany L; Boucherie DM; Creeney H; van Drie RWA; Farham F; Favaretto S; Gollion C; Grangeon L; Lyons H; Marschollek K; Onan D; Pensato U; Stanyer E; Waliszewska-Prosół M; Wiels W; Chen HZ; Amin FM;
J Headache Pain; 2023 Jun; 24(1):76. PubMed ID: 37370051
[TBL] [Abstract][Full Text] [Related]
4. Role of PACAP in migraine: An alternative to CGRP?
Guo S; Jansen-Olesen I; Olesen J; Christensen SL
Neurobiol Dis; 2023 Jan; 176():105946. PubMed ID: 36481434
[TBL] [Abstract][Full Text] [Related]
5. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
[TBL] [Abstract][Full Text] [Related]
6. Targets for migraine treatment: beyond calcitonin gene-related peptide.
Moreno-Ajona D; Villar-Martínez MD; Goadsby PJ
Curr Opin Neurol; 2021 Jun; 34(3):363-372. PubMed ID: 33840777
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment.
Dominguez-Moreno R; Do TP; Ashina M
Curr Opin Endocrinol Diabetes Obes; 2022 Apr; 29(2):225-231. PubMed ID: 35066541
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.
Haanes KA; Edvinsson L
CNS Drugs; 2019 Jun; 33(6):525-537. PubMed ID: 30989485
[TBL] [Abstract][Full Text] [Related]
9. Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects.
Lukacs M; Tajti J; Fulop F; Toldi J; Edvinsson L; Vecsei L
Curr Med Chem; 2017; 24(33):3649-3665. PubMed ID: 28707585
[TBL] [Abstract][Full Text] [Related]
10. Targeting BK
Al-Karagholi MA; Gram C; Nielsen CAW; Ashina M
CNS Drugs; 2020 Apr; 34(4):325-335. PubMed ID: 32060729
[TBL] [Abstract][Full Text] [Related]
11. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
Pérez-Pereda S; Toriello-Suárez M; Ocejo-Vinyals G; Guiral-Foz S; Castillo-Obeso J; Montes-Gómez S; Martínez-Nieto RM; Iglesias F; González-Quintanilla V; Oterino A
Mol Biol Rep; 2020 Sep; 47(9):7125-7138. PubMed ID: 32951099
[TBL] [Abstract][Full Text] [Related]
12. Emerging and future directions of migraine research and treatment.
Chiang CC; Dodick DW
Handb Clin Neurol; 2024; 199():583-597. PubMed ID: 38307672
[TBL] [Abstract][Full Text] [Related]
13. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
Do TP; Al-Saoudi A; Ashina M
Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
[TBL] [Abstract][Full Text] [Related]
14. A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond.
Garelja ML; Hay DL
Headache; 2022 Oct; 62(9):1093-1104. PubMed ID: 36226379
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide.
Moldovan Loomis C; Dutzar B; Ojala EW; Hendrix L; Karasek C; Scalley-Kim M; Mulligan J; Fan P; Billgren J; Rubin V; Boshaw H; Kwon G; Marzolf S; Stewart E; Jurchen D; Pederson SM; Perrino McCulloch L; Baker B; Cady RK; Latham JA; Allison D; Garcia-Martinez LF
J Pharmacol Exp Ther; 2019 Apr; 369(1):26-36. PubMed ID: 30643015
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment.
Santos-Lasaosa S; Belvís R; Cuadrado ML; Díaz-Insa S; Gago-Veiga A; Guerrero-Peral AL; Huerta M; Irimia P; Láinez JM; Latorre G; Leira R; Pascual J; Porta-Etessam J; Sánchez Del Río M; Viguera J; Pozo-Rosich P
Neurologia (Engl Ed); 2022 Jun; 37(5):390-402. PubMed ID: 35672126
[TBL] [Abstract][Full Text] [Related]
19. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
20. Shared and independent roles of CGRP and PACAP in migraine pathophysiology.
Kuburas A; Russo AF
J Headache Pain; 2023 Apr; 24(1):34. PubMed ID: 37009867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
